Boston Scientific is trading 4.11% up at $43.70, with broader U.S. market gains the most likely context. - The S&P 500, Nasdaq and Dow are all higher, and no clear company-specific news explains the move. - Recent coverage noted a lowered analyst price target and an October 30 downgrade. The latest reported quarter modestly beat sales estimates but included reduced full-year earnings guidance; these developments do not clearly explain Monday’s gain.